Navigation Links
Cardium Announces Investor Presentation and Corporate Update Webcast
Date:12/3/2008

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announces that the Company will be presenting a webcast providing an investor presentation, corporate update and review of its ongoing business strategies and plans. The webcast will be presented following the close of market today at 4:30 PM (Eastern Time) and can be accessed at http://www.investorcalendar.com/IC/CEPage.asp?ID=138418 at that time. The webcast will also be accessible for the following thirty days via the Investors section at "Calendar of Events" on the Company's website at http://www.cardiumthx.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Forward-Looking Statements in Webcast

Except for statements of historical fact, the matters discussed in the webcast are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. Actual results may also differ substantially from those described in or contemplated by the webcast due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties inherent in the conduct of human clinical trials, including the timing, costs and results of such trials, our limited experience in the development, testing and marketing of therapeutic hypothermia devices, uncertainties regarding potential corporate development partners, our dependence upon proprietary technology, uncertainties regarding ongoing needs to support product development programs and other cash expenditures, our history of operating losses and accumulated deficits, risks and uncertainties related to our ability to raise cash under difficult capital market conditions, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium

                              Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are
                     trademarks of Tissue Repair Company.
       InnerCool Therapies(R), InnerCool(R), Celsius Control System(R),
  RapidBlue(TM), CoolBlue(TM), Accutrol(R), Temperature Control Element(R),
      TCE(R) and UroCool(TM) are trademarks of InnerCool Therapies, Inc.

'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardium Completes $6.0 Million Financing
2. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Reports on Recent Highlights and Financial Results
5. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
6. AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers
7. Lucas Group Announces Their Executive Recruitment Military Hiring Conference Schedule for December 2008
8. Axiom Consulting Partners Announces the Results of its Return On Sales Investment Survey
9. United American Healthcare Corporation Announces Stock Repurchase Program
10. eOn Communications Announces GSA Contract
11. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: